This site is intended for health professionals only
Monday 27 May 2019
Share |

Topic: psoriasis

September 18, 2017
More than 80% of patients receiving guselkumab, including patients transitioned from HUMIRA® (adalimumab) to the anti-interleukin (IL)-23 monoclonal antibody, demonstrated PASI 90 and IGA 0/1 scores at week 100

Janssen Research & Development has presented new longer-term data from the open-label extension of the VOYAGE 1 trial demonstrating consistent rates of skin clearance with guselkumab treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 monoclonal antibody.1

 

July 20, 2017
First and only biologic that selectively targets the IL-17 receptor subunit A

LEO Pharma has announced that the European Commission has granted marketing authorisation for Kyntheum® (brodalumab), a biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy.1

 

Kyntheum® is the first and only biologic that selectively targets the IL-17 receptor subunit A.2,3

 

April 5, 2017
A report by the Economist Intelligence Unit also highlights inequality in access to support and effective treatment for those living with psoriasis
A new report by the Economist Intelligence Unit (EIU) reveals governments have taken little or no action to improve care for those living with psoriasis, a chronic autoimmune disease of the skin that affects 125 million people worldwide, since the 2014 World Health Organisation (WHO) Resolution, which called for global action to improve quality of life for those living with the disease.1,2,3,4
 
 
July 7, 2016
As a first-of-its kind, the confirmatory clinical safety and efficacy study compares originator etanercept to a biosimilar candidate in psoriasis

Sandoz has announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.

 

The study compared the safety and efficacy of its biosimilar etanercept candidate with the originator product, Enbrel® in patients with moderate-to-severe chronic plaque-type psoriasis and was presented at Psoriasis 2016, the 5th Congress of the Psoriasis International Network (PIN), Paris, France.

 

March 3, 2016
Study will evaluate efficacy, safety and immunogenicity of adalimumab biosimilar candidate MSB11022 compared with Humira®

Merck, a leading science and technology company, announced the initiation of a global Phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This milestone is a strong reflection of Merck’s progress in biosimilars, with the goal of delivering high-quality biologics to patients all over the world.
 

February 29, 2016
Eli Lilly and Company announced that ixekizumab [TALTZ®] has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use

Eli Lilly and Company announced that ixekizumab [TALTZ®] has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy,1 Ixekizumab is specifically designed to target the cytokine interleukin IL-17A, a protein that plays a key role in driving underlying inflammation in psoriasis.2

 

February 29, 2016
The National Ankylosing Spondylitis Society (NASS) has launched a new campaign aimed at ophthalmologists, dermatologists and gastroenterologists called Back Pain Plus

The National Ankylosing Spondylitis Society (NASS) has launched a new campaign aimed at ophthalmologists, dermatologists and gastroenterologists called Back Pain Plus. The initiative aims to encourage professionals in these fields to think about the link between axial spondyloarthritis including ankylosing spondylitis (AS) and acute anterior uveitis (AAU), psoriasis and inflammatory bowel disease (IBD).
 

As it stands:

September 30, 2015
Celgene working with NICE to ensure OTEZLA is made available to patients in England and Wales as soon as possible

The National Institute for Health Care and Excellence (NICE) has issued a Final Appraisal Determination (FAD) not recommending OTEZLA® (apremilast), a novel oral treatment for adults with moderate to severe plaque psoriasis, for use within NHS England and Wales. (1)

 

December 3, 2014
On the International Day of Persons with Disabilities, the International Federation of Psoriasis Associations, IFPA, launches an issue brief highlighting the physical and social barriers that people with psoriasis and psoriatic arthritis face, calling governments around the world to action.

On the International Day of Persons with Disabilities, the International Federation of Psoriasis Associations, IFPA, launches an issue brief highlighting the physical and social barriers that people with psoriasis and psoriatic arthritis face, calling governments around the world to action.

November 21, 2014
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA® (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications.

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA® (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: (1)
 

October 29, 2014
On World Psoriasis Day, the International Federation of Psoriasis Associations, IFPA, brings attention to the tools respondents from 90 countries have identified to help build a better world for people with psoriasis, by participating in an online survey launched in June. The preliminary results of the survey show a clear consensus – the top tool voted for is Educating the patients about treatment options.

On World Psoriasis Day, the International Federation of Psoriasis Associations, IFPA, brings attention to the tools respondents from 90 countries have identified to help build a better world for people with psoriasis, by participating in an online survey launched in June. The preliminary results of the survey show a clear consensus – the top tool voted for is Educating the patients about treatment options.

October 29, 2014
Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis* showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet® gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians’ assessments of disease severity.

Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis* showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet® gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians’ assessments of disease severity. (1)

October 13, 2014
Janssen-Cilag International NV reported new findings at the annual meeting of the European Academy of Dermatology and Venereology (EADV) showing significantly better persistency and lower rates of discontinuation with STELARA® (ustekinumab) therapy in comparison to anti-tumour necrosis factor (TNF)-alpha treatments among patients participating in Psoriasis Longitudinal Assessment and Registry (PSOLAR), a post-marketing registry following patients with moderate to severe plaque psoriasis.

Janssen-Cilag International NV reported new findings at the annual meeting of the European Academy of Dermatology and Venereology (EADV) showing significantly better persistency and lower rates of discontinuation with STELARA® (ustekinumab) therapy in comparison to anti-tumour necrosis factor (TNF)-alpha treatments among patients participating in Psoriasis Longitudinal Assessment and Registry (PSOLAR), a post-marketing registry following patients with moderate to severe plaque psoriasis. 

 

May 12, 2014
The thinking behind the Global Psoriasis Atlas is to fill the gaps in the understanding of the prevalence and burden of psoriasis.

The thinking behind the Global Psoriasis Atlas is to fill the gaps in the understanding of the prevalence and burden of psoriasis.

The International Federation of Psoriasis Associations (IFPA), the International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC) are the bodies behind the enterprise.

September 23, 2009
Janssen-Cilag's Stelara approved by NICE for the treatment of moderate to severe plaque psoriasis

teaser

January 26, 2009
Sufferers of psoriasis may benefit from findings that genetic variants might be involved in its development

teaser

January 23, 2009
New biologic Stelara receives approval in Europe for treatment of moderate to severe plaque psoriasis

teaser

September 19, 2008
Ustekinumab demonstrates superior efficacy to Enbrel in moderate to severe plaque psoriasis

teaser

July 9, 2008
Psoriasis treatment receives approval for once weekly dosage

teaser

June 26, 2008
New guidance has been issued on the use of adalimumab for the treatment of psoriasis

teaser

June 20, 2008
The DODAC of the FDA has unanimously recommended the approval of ustekinumab in psoriasis

teaser

May 21, 2008
Two large studies find that ustekinumab is effective for treating psoriasis

teaser

March 3, 2008
One-year data from the Phase III study PHOENIX 1 showed therapy with ustekinumab given every 12 weeks provided improvement in the treatment of moderate to severe plaque psoriasis

teaser

December 24, 2007
The European Commission has issued Abbott with marketing authorisation for Humira (adalimumab) to be used as a treatment for moderate-to-severe plaque psoriasis

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine